The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer

Radiotherapy can convert malignant cells into an in situ anticancer vaccine, but is often inadequate at generating sufficient pro-inflammatory signals to optimally activate innate and adaptive immune responses. Topical imiquimod is a powerful pro-inflammatory agent with clinical activity against sup...

Descripción completa

Detalles Bibliográficos
Autores principales: Demaria, Sandra, Vanpouille-Box, Claire, Formenti, Silvia C, Adams, Sylvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881106/
https://www.ncbi.nlm.nih.gov/pubmed/24404422
http://dx.doi.org/10.4161/onci.25997
_version_ 1782298163408797696
author Demaria, Sandra
Vanpouille-Box, Claire
Formenti, Silvia C
Adams, Sylvia
author_facet Demaria, Sandra
Vanpouille-Box, Claire
Formenti, Silvia C
Adams, Sylvia
author_sort Demaria, Sandra
collection PubMed
description Radiotherapy can convert malignant cells into an in situ anticancer vaccine, but is often inadequate at generating sufficient pro-inflammatory signals to optimally activate innate and adaptive immune responses. Topical imiquimod is a powerful pro-inflammatory agent with clinical activity against superficial skin cancers. These two modalities appear to complement each other, hence achieving local and systemic tumor control.
format Online
Article
Text
id pubmed-3881106
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38811062014-01-08 The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer Demaria, Sandra Vanpouille-Box, Claire Formenti, Silvia C Adams, Sylvia Oncoimmunology Author's View Radiotherapy can convert malignant cells into an in situ anticancer vaccine, but is often inadequate at generating sufficient pro-inflammatory signals to optimally activate innate and adaptive immune responses. Topical imiquimod is a powerful pro-inflammatory agent with clinical activity against superficial skin cancers. These two modalities appear to complement each other, hence achieving local and systemic tumor control. Landes Bioscience 2013-10-01 2013-09-24 /pmc/articles/PMC3881106/ /pubmed/24404422 http://dx.doi.org/10.4161/onci.25997 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Demaria, Sandra
Vanpouille-Box, Claire
Formenti, Silvia C
Adams, Sylvia
The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
title The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
title_full The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
title_fullStr The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
title_full_unstemmed The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
title_short The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
title_sort tlr7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881106/
https://www.ncbi.nlm.nih.gov/pubmed/24404422
http://dx.doi.org/10.4161/onci.25997
work_keys_str_mv AT demariasandra thetlr7agonistimiquimodasanadjuvantforradiotherapyelicitedinsituvaccinationagainstbreastcancer
AT vanpouilleboxclaire thetlr7agonistimiquimodasanadjuvantforradiotherapyelicitedinsituvaccinationagainstbreastcancer
AT formentisilviac thetlr7agonistimiquimodasanadjuvantforradiotherapyelicitedinsituvaccinationagainstbreastcancer
AT adamssylvia thetlr7agonistimiquimodasanadjuvantforradiotherapyelicitedinsituvaccinationagainstbreastcancer
AT demariasandra tlr7agonistimiquimodasanadjuvantforradiotherapyelicitedinsituvaccinationagainstbreastcancer
AT vanpouilleboxclaire tlr7agonistimiquimodasanadjuvantforradiotherapyelicitedinsituvaccinationagainstbreastcancer
AT formentisilviac tlr7agonistimiquimodasanadjuvantforradiotherapyelicitedinsituvaccinationagainstbreastcancer
AT adamssylvia tlr7agonistimiquimodasanadjuvantforradiotherapyelicitedinsituvaccinationagainstbreastcancer

Ejemplares similares